The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Peptides / Macrocycle Drug Discovery Services and Platforms Market by Type of Product (Synthetic Peptides, Biological, Recombinant Peptides, Macrocycles), Drug Discovery Steps (Target Identification / Validation, Hit Identification, Lead Generation / Lead Optimization), Therapeutic Area (Oncological, Metabolic, Cardiovascular, Infections, Urological, Endocrine), Company Size (Small, Mid-sized, Large and Very Large Companies) and Key Geographies: Industry Trends and Global Forecasts, 2020-2030

  • Lowest Price Guaranteed From USD 4,899

  • Published
    February 2020

  • Pages
    240

  • View Count
    4508

Example Insights

Peptides and Macrocycle Drug Discovery Services and Platforms Market, 2020 - 2030-Context Peptides and Macrocycle Drug Discovery Services and Platforms Market, 2020 - 2030-Service Providers Peptides and Macrocycle Drug Discovery Services and Platforms Market, 2020 - 2030-Platform Providers
Peptides and Macrocycle Drug Discovery Services and Platforms Market, 2020 - 2030-Competitiveness Analysis Peptides and Macrocycle Drug Discovery Services and Platforms Market, 2020 - 2030-Partnerships & Collaborations Peptides and Macrocycle Drug Discovery Services and Platforms Market, 2020 - 2030-Segmentation

 

Overview

Over the past few years, peptides (including oligopeptides, polypeptides and synthetic peptides) and macrocycle-based pharmacological interventions have gained a lot of attention from clinical researchers; drug development efforts focused on such molecules have significantly increased. This can be attributed to the benefits offered by the aforementioned drug classes, which include high target specificity, low toxicity and favorable safety profiles. ,   In fact, more than 60 peptide-based therapies and macrocycle drug molecules have been approved till date, across the globe. In addition, more than 400 peptide based drugs are currently being evaluated in clinical trials, while over 500 molecules are still in the early stages of development.  

It has been reported that the overall process of drug development, from discovery of a molecule to its commercial launch, takes around 10-15 years and involves capital investments worth USD 4-10 billion. However, only a small proportion of the molecules, which are selected for further investigation during the initial stages of research, actually enter the market. Given the complexities associated with the drug discovery process, the overall research and development (R&D) expenditure in the pharmaceutical / biotechnology sector has steadily increased over time. Specifically, the discovery of peptides and macrocycles for therapeutic use is a long, arduous and cost intensive process. As a result, many developers are opting to outsource such operations to contract research organizations (CROs) that claim to specialize in this regard. In addition, there are multiple technology platform providers, which offer licenses to proprietary peptide discovery platforms that can be used by interested drug developers / manufacturers. We believe that, as the demand for peptide-based therapeutics increases, the opportunity for contract service provides and technology developers engaged in this domain is also likely to grow in the foreseen future.

Scope of the Report

The “Peptides and Macrocycle Drug Discovery: Services and Platforms Market, 2020-2030” report features an extensive study on the current market landscape and future of companies offering services for peptides and macrocycle drug discovery operations. The study includes in-depth analyses, highlighting the capabilities of various service / technology providers engaged in this market. Amongst other elements, the report includes:

  • A detailed assessment of the current market landscape of companies offering peptide and macrocycle drug discovery services, including developer information (year of establishment, company size and location of headquarters), type of peptide manufactured (linear, cyclic, helical and others), drug discovery steps covered in service portfolio (target validation, hit identification, lead generation and lead optimization), peptide generation methods used (liquid phase synthesis, solid phase synthesis, microwave-assisted synthesis, recombinant methods and others), peptide modification services (C-terminal, N-terminal, fret / quenching tags, immunogenic conjugates, linkers / spacers, unnatural AAS, cyclization, stable isotope labels and post-translational modification services) and other services offered (peptide isolation / purification service, peptide detection / identification service and peptide quantification service).
  • An insightful geographical benchmarking of the capabilities of companies of various sizes, highlighting the key focus areas, comparing their existing strengths both within and beyond their respective peer groups (based on geography and company size). 
  • An in-depth analysis of peptide platform and library service providers, featuring information on their company details (year of establishment, company size and location of headquarters), purpose of the platform, type of peptide manufactured (linear, cyclic, helical and others) and platform access model (pipeline licensing, technology licensing, strategic alliance and library provider).
  • Profiles of peptides and macrocycle drug discovery service providers, featuring information on the year of establishment, location of headquarters, peptide discovery service / platform portfolio, recent developments and an informed future outlook.
  • An analysis of the partnerships that have been established in the recent past, covering R&D agreements, licensing agreements, acquisitions and other form of collaborations.

One of the key objectives of the report was to estimate the existing market size and the future growth potential within the peptides and macrocycle drug discovery services market. Based on multiple parameters, such as R&D spend, we have developed an informed estimate on the financial evolution of the market over the period, 2020-2030. The report also provides details on the likely distribution of the current and forecasted opportunity across [A] different type of product (synthetic peptides, biological and recombinant peptides and macrocycles), [B]  drug discovery steps (target identification and validation, hit identification, lead generation and lead optimization), [C] therapeutic area (oncological disorders, metabolic disorders, cardiovascular disorders, infectious disorders, urological disorders, endocrine disorders, CNS disorders, and other diseases), [D] company size (small, mid-sized and large and very large companies) and [E] geography (North America, Europe, Asia Pacific). To account for the uncertainties associated with the drug discovery services and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution. 

The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interview(s) held with the following industry stakeholders:

  • Mark L Peterson (Chief Operating Officer, Cyclenium Pharma)
  • Anonymous

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the peptide and macrocycles discovery services and platforms market and its likely evolution in the short-mid and long terms.

Chapter 3 provides a general overview of peptides and macrocycle drugs, along with information on their historical background, structure and classes, and details related to their affiliated drug discovery processes, including synthesis procedures and requirement for further modification. It also lists the various bioanalytical techniques used in the isolation, detection and quantification of peptides, along with information on their storage and delivery. The chapter features a brief description of the factors that need to be taken into consideration while selecting a suitable CRO partner for peptide discovery.

Chapter 4 includes a detailed market landscape analysis of companies that offer peptide and macrocycles discovery services. It includes information related to over 35 companies that are actively involved in peptides and macrocycles drug discovery services, presenting detailed analyses on the basis of their company information (year of establishment, company size and geographical location), type of peptide manufactured (linear, cyclic, helical and others), services for drug discovery steps (target identification and validation, hit identification, lead generation and lead optimization), peptide generation methods (liquid phase synthesis, solid phase synthesis, microwave-assisted synthesis, recombinant methods and others), peptide modification services (C-terminal, N-terminal, fret / quenching tags, immunogenic conjugates, linkers / spacers, unnatural AAS, cyclization, stable isotope labels and post-translational modification services), and other services (peptide isolation / purification service, peptide detection / identification service and peptide quantification service).  

Chapter 5 presents a benchmark analysis, highlighting the capabilities of small, mid-sized and large companies in terms of their service portfolio. Further, the analysis allows companies to compare their existing capabilities within and beyond their respective peer groups (basis of geography and company size, separately), providing a means for stakeholders to identify ways to gain a competitive edge in the industry.

Chapter 6 features detailed profiles of popular players that specialize in providing services for peptides and macrocycles discovery. Each profile features an overview of the company, its service portfolio, details on manufacturing facilities, and an informed future outlook.

Chapter 7 includes a comprehensive market landscape analysis of companies that offer peptides and macrocycles discovery platforms and library services. It includes information related to over 20 companies, presenting detailed analysis on the basis of their company information (year of establishment, company size and geographical location), name and purpose of the platform, type of peptides manufactured using that platform (linear, cyclic, helical and others) and accessibility of the platforms (pipeline licensing, technology licensing, strategic alliance and library provider). 

Chapter 8 features an analysis of the various collaborations and partnerships that have been inked amongst players in this market. We have also discussed the different partnership models (including R&D agreements, licensing agreements, acquisitions and others) and the most common forms of deals / agreements that have been established in the period between 2015 to 2019.

Chapter 9 presents an insightful market forecast analysis, highlighting the growth of the peptide drug discovery services market till 2030. In order to provide details on the future opportunity, our projections have been segmented on the basis of [A] type of product (synthetic peptides, biological and recombinant peptides and macrocycles),  [B] drug discovery steps (target identification and validation, hit identification, lead generation and lead optimization), [C] therapeutic area (oncological disorders, metabolic disorders, cardiovascular disorders, infectious disorders, urological disorders, endocrine disorders, CNS disorders, and other diseases), [D] size of the company (small, mid-sized and large and very large companies) and [E] geography (North America, Europe, and Asia Pacific).  

Chapter 10 provides a discussion on affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, featuring a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on the overall medical devices labeling industry.

Chapter 11 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario. Further, it captures the evolutionary trends that are likely to determine the future of the peptides and macrocycles discovery industry.

Chapter 12 is a collection of interview transcripts of the discussions that were held with key stakeholders in this market. The chapter provides details of interview(s) held with Mark L Peterson (Chief Operating Officer, Cyclenium Pharma) and anonymous.

Chapter 13 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 14 is an appendix, which contains a list of companies and organizations mentioned in this report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. History of Peptide Drugs
3.3. Structure of Peptides
3.4. Major Classes of Peptides
3.4.1. Dipeptides
3.4.2. Depsipeptides
3.4.3. Cyclic Peptides / Macrocycles
3.4.4. Other Types of Peptides

3.5. Steps Involved in the Discovery of Peptides
3.6. Synthesis of Peptides
3.7. Modification of Peptides
3.8. Tools and Techniques for Peptide Analysis
3.9. Delivery of Peptides
3.10. Applications of Peptides

3.11. Role of Contract Research Organizations (CROs) in Drug Discovery
3.12. Risks Associated with Outsourcing Research Operations
3.13. Key Considerations for Selecting a Suitable CRO Partner

4. MARKET LANDSCAPE OF SERVICE PROVIDERS
4.1. Chapter Overview
4.2. Peptides and Macrocycle Drug Discovery Service Providers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Type of Peptide
4.2.5. Analysis by Drug Discovery Steps
4.2.6. Analysis by Peptide Generation Method Used
4.2.7. Analysis by Peptide Modification Method Used
4.2.8. Analysis by Other Services Offered

5. BENCHMARK ANALYSIS
5.1. Chapter Overview
5.2. Methodology
5.3. Benchmarking by Region
5.3.1. Europe, Peer Group I
5.3.2. North America, Peer Group II
5.3.3. Asia Pacific, Peer Group III

5.4. Benchmarking by Company Size
5.4.1. Small Companies, Peer Group I
5.4.2. Mid-Sized Companies, Peer Group II
5.4.3. Large and Very Large Companies, Peer Group III

5.5. Concluding Remarks

6. MARKET LANDSCAPE OF PLATFORM PROVIDERS
6.1. Chapter Overview
6.2. Peptides and Macrocycle Drug Discovery Platform Providers: Overall Market Landscape
6.2.1. Analysis by Year of Establishment
6.2.2. Analysis by Company Size
6.2.3. Analysis by Location of Headquarters
6.2.4. Analysis by Type of Peptide
6.2.5. Analysis by Platform Access Model

7. COMPANY PROFILES
7.1. Chapter Overview
7.2. Peptides and Macrocycle Drug Discovery Service Providers
7.2.1. GenScript
7.2.1.1. Company Overview
7.2.1.2. Service Portfolio
7.2.1.3. Future Outlook

7.2.2. JPT Peptide Technologies
7. 2.2.1. Company Overview
7. 2.2.2. Service Portfolio
7. 2.2.3. Future Outlook

7.2.3. CPC Scientific
7.2.3.1. Company Overview
7.2.3.2. Service Portfolio
7.2.3.3. Future Outlook

7.2.4. IRBM
7.2.4.1. Company Overview
7.2.4.2. Service Portfolio
7.2.4.3. Future Outlook

7.2.5. Creative Peptides
7.2.5.1. Company Overview
7.2.5.2. Service Portfolio
7.2.5.3. Future Outlook

7.2.6. Pepscan
7.2.6.1. Company Overview
7.2.6.2. Service Portfolio
7.2.6.3. Future Outlook

7.3 Peptides and Macrocycle Drug Discovery Platform Providers
7.3.1. Interprotein
7.3.1.1. Company Overview
7.3.1.2. Peptide Discovery Platform
7.3.1.3. Future Outlook

7.3.2. RA Pharmaceuticals
7. 3.2.1. Company Overview
7. 3.2.2. Peptide Discovery Platform
7. 3.2.3. Future Outlook

7.3.3. Pepticom
7.3.3.1. Company Overview
7.3.3.2. Peptide Discovery Platform
7.3.3.3. Future Outlook

7.3.4. PeptiDream
7.3.4.1. Company Overview
7.3.4.2. Peptide Discovery Platform
7.3.4.3. Future Outlook

7.3.5. Creative Biolabs
7.3.5.1. Company Overview
7.3.5.2. Peptide Discovery Platform
7.3.5.3. Future Outlook

7.3.6. MeSCue-Janusys
7.3.6.1. Company Overview
7.3.6.2. Peptide Discovery Platform
7.3.6.3. Future Outlook

8. PARTNERSHIPS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Peptides and Macrocycle Drug Discovery Service and Platform Providers: List of Partnerships
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Year and Type of Partnership
8.3.4. Analysis by Type of Peptide
8.3.5. Analysis by Focus Area
8.3.6. Most Active Players: Analysis by Number and Type of Partnership
8.3.7. Geographical Analysis
8.3.7.1. Continent-wise Distribution
8.3.7.2. Country-wise Distribution

9. MARKET FORECAST AND OPPORTUNITY ANALYSIS
9.1. Chapter Overview
9.2. Key Assumptions and Forecast Methodology
9.3. Overall Peptide Drug Discovery Services Market, 2020-2030
9.4. Peptide Drug Discovery Services Market: Analysis by Type of Peptide, 2020, 2025 and 2030
9.4.1. Peptide Drug Discovery Services Market for Synthetic Peptides, 2020-2030
9.4.2. Peptide Drug Discovery Services Market for Biologic and Recombinant Peptides, 2020-2030
9.4.3. Peptide Drug Discovery Services Market for Macrocycles, 2020-2030

9.5. Peptide Drug Discovery Services Market: Analysis by Drug Discovery Steps, 2020, 2025 and 2030
9.5.1. Peptide Drug Discovery Services Market for Target Identification and Validation, 2020-2030
9.5.2. Peptide Drug Discovery Services Market for Hit Identification, 2020-2030
9.5.3. Peptide Drug Discovery Services Market for Lead Generation, 2020-2030
9.5.4. Peptide Drug Discovery Services Market for Lead Optimization, 2020-2030

9.6. Peptide Drug Discovery Services Market: Analysis by Therapeutic Area, 2020-2030
9.6.1. Peptide Drug Discovery Services Market for Oncological Disorders, 2020-2030
9.6.2. Peptide Drug Discovery Services Market for Metabolic Disorders, 2020-2030
9.6.3. Peptide Drug Discovery Services Market for Cardiovascular Disorders, 2020-2030
9.6.4. Peptide Drug Discovery Services Market for Infectious Diseases, 2020-2030
9.6.5. Peptide Drug Discovery Services Market for Urological Disorders, 2020-2030
9.6.6. Peptide Drug Discovery Services Market for Endocrine Disorders, 2020-2030
9.6.7. Peptide Drug Discovery Services Market for CNS Disorders, 2020-2030
9.6.8. Peptide Drug Discovery Services Market for Other Diseases, 2020-2030

9.7. Peptide Drug Discovery Services Market: Analysis by Company Size, 2020-2030
9.7.1. Peptide Drug Discovery Services Market for Small Companies, 2020-2030
9.7.2. Peptide Drug Discovery Services Market for Mid-Sized Companies, 2020-2030
9.7.3. Peptide Drug Discovery Services Market for Large and Very Large Companies, 2020-2030

9.8. Peptide Drug Discovery Services Market: Analysis by Geography, 2020, 2025 and 2030
9.8.1. Peptide Drug Discovery Services Market in North America, 2020-2030
9.8.2. Peptide Drug Discovery Services Market in Europe, 2020-2030
9.8.3. Peptide Drug Discovery Services Market in Asia Pacific, 2020-2030

10. SWOT ANALYSIS
10.1. Chapter Overview
10.2. Strengths
10.3. Weaknesses
10.4. Opportunities
10.5. Threats
10.6. Concluding Remarks

11. CONCLUSION
11.1. Chapter Overview
11.2. Key Takeaways

12. INTERVIEW TRANSCRIPTS
12.1. Chapter Overview
12.2. Mark L Peterson (Chief Operating Officer, Cyclenium Pharma)
12.3. Anonymous

13. APPENDIX 1: TABULATED DATA

14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Historical Overview of Peptide Drugs
Figure 3.2 Primary Structure of Peptides
Figure 3.3 Secondary Structure of Peptides
Figure 3.4 Tertiary Structure of Peptides
Figure 3.6 Quaternary Structure of Peptides
Figure 3.7 Key Strategies for Peptide Synthesis
Figure 3.8 Tools and Techniques for Peptide Analysis
Figure 3.9 Key Considerations for Selecting a Suitable CRO Partner
Figure 3.10 Risks and Challenges Associated with CROs
Figure 4.1 Peptides and Macrocycle Drug Discovery Service Providers: Distribution by Year of Establishment
Figure 4.2 Peptides and Macrocycle Drug Discovery Service Providers: Distribution by Company Size
Figure 4.3 Peptides and Macrocycle Drug Discovery Service Providers: Distribution by Location of Headquarters (Region-wise)
Figure 4.4 Peptides and Macrocycle Drug Discovery Service Providers: Distribution by Location of Headquarters (Country-wise)
Figure 4.5 Peptides and Macrocycle Drug Discovery Service Providers: Distribution by Type of Peptide
Figure 4.6 Peptides and Macrocycle Drug Discovery Service Providers: Distribution by Drug Discovery Steps
Figure 4.7 Peptides and Macrocycle Drug Discovery Service Providers: Distribution by Peptide Generation Method Used
Figure 4.8 Peptides and Macrocycle Service Providers: Analysis by Peptide Modification Method Used
Figure 4.9 Peptides and Macrocycles Service Providers: Analysis by Other Services Offered
Figure 5.1 Benchmark Analysis: Regional Distribution of Companies
Figure 5.2 Benchmark Analysis: Europe Based Companies, Peer Group I
Figure 5.3 Benchmark Analysis: North America Based Companies, Peer Group II
Figure 5.4 Benchmark Analysis: Asia Pacific Based Companies, Peer Group III
Figure 5.5 Benchmark Analysis: Distribution of Companies by Company Size
Figure 5.6 Benchmark Analysis: Small Companies, Peer Group I
Figure 5.7 Benchmark Analysis: Mid-Sized Companies, Peer Group II
Figure 5.8 Benchmark Analysis: Large and Very Large Companies, Peer Group III
Figure 5.9 Benchmark Analysis: Comparison of Services and Capabilities across Different Peer Groups (Based on Region)
Figure 5.10 Benchmark Analysis: Comparison of Services and Capabilities across Different Peer Groups (Based on Company Size)
Figure 6.1 Peptides and Macrocycle Drug Discovery Platform Providers: Distribution by Year of Establishment
Figure 6.2 Peptides and Macrocycle Drug Discovery Platform Providers: Distribution by Company Size
Figure 6.3 Peptides and Macrocycle Drug Discovery Platform Providers: Distribution by Location of Headquarters (Region-wise)
Figure 6.4 Peptides and Macrocycle Drug Discovery Platform Providers: Distribution by Location of Headquarters (Country-wise)
Figure 6.5 Peptides and Macrocycle Drug Discovery Platform Providers: Distribution by Type of Peptide
Figure 6.6 Peptides and Macrocycles Drug Discovery Platform Providers: Distribution by Platform Access Model
Figure 7.1 GenScript: Peptide Discovery Services
Figure 7.2 JPT Peptide Technologies: Peptide Discovery Services
Figure 7.3 CPC Scientific: Peptide Discovery Services
Figure 7.4 IRBM: Peptide Discovery Services
Figure 7.5 Creative Peptides: Peptide Discovery Services
Figure 7.6 Pepscan: Peptide Discovery Services
Figure 7.7 Interprotein Corporation: Peptide Drug Discovery Platform Overview
Figure 7.8 RA Pharmaceuticals: Peptide Drug Discovery Platform Overview
Figure 7.9 Pepticom: Peptide Drug Discovery Platform Overview
Figure 7.10 PeptiDream: Peptide Drug Discovery Platform Overview
Figure 7.11 Creative Biolabs: Peptide Drug Discovery Platform Overview
Figure 7.12 MeSCue-Janusys: Peptide Drug Discovery Platform Overview
Figure 8.1 Peptides and Macrocycle Drug Discovery Services and Platforms: Cumulative Distribution by Year of Partnership
Figure 8.2 Peptides and Macrocycle Drug Discovery Services and Platforms: Distribution by Type of Partnership
Figure 8.3 Peptides and Macrocycle Drug Discovery Services and Platforms: Cumulative Year-Wise Distribution by Type of Partnership
Figure 8.4 Peptides and Macrocycle Drug Discovery Services and Platforms: Distribution by Type of Peptide
Figure 8.5 Peptides and Macrocycle Drug Discovery Services and Platforms: Distribution by Key Focus Areas
Figure 8.6 Peptides and Macrocycle Drug Discovery Services and Platforms: Most Active Players
Figure 8.7 Peptides and Macrocycle Drug Discovery Services and Platforms: Country-wise Distribution
Figure 8.8 Peptides and Macrocycle Drug Discovery Services and Platforms: Continent-wise Distribution
Figure 9.1 Overall Peptide Drug Discovery Services Market, Base Scenario, 2020-2030 (USD Million)
Figure 9.2 Peptide Drug Discovery Services Market: Distribution by Type of Peptide, 2020, 2025 and 2030
Figure 9.3 Peptide Drug Discovery Services Market: Synthetic Peptides, Base Scenario, 2020-2030 (USD Million)
Figure 9.4 Peptide Drug Discovery Services Market: Biologic and Recombinant Peptides, Base Scenario, 2020-2030 (USD Million)
Figure 9.5 Peptide Drug Discovery Services Market: Macrocycles, Base Scenario, 2020-2030 (USD Million)
Figure 9.6 Peptide Drug Discovery Services Market: Distribution by Drug Discovery Steps, 2020, 2025 and 2030
Figure 9.7 Peptide Drug Discovery Services Market: Target Identification and Validation, Base Scenario, 2020-2030 (USD Million)
Figure 9.8 Peptide Drug Discovery Services Market: Hit Identification, Base Scenario, 2020-2030 (USD Million)
Figure 9.9 Peptide Drug Discovery Services Market: Lead Generation, Base Scenario, 2020-2030 (USD Million)
Figure 9.10 Peptide Drug Discovery Services Market: Lead Optimization, Base Scenario, 2020-2030 (USD Million)
Figure 9.11 Peptide Drug Discovery Services Market: Distribution by Therapeutic Area, 2020, 2025 and 2030
Figure 9.12 Peptide Drug Discovery Services Market: Oncological Disorders, Base Scenario, 2020-2030 (USD Million)
Figure 9.13 Peptide Drug Discovery Services Market: Metabolic Disorders, Base Scenario, 2020-2030 (USD Million)
Figure 9.14 Peptide Drug Discovery Services Market: Cardiovascular Disorders, Base Scenario, 2020-2030 (USD Million)
Figure 9.15 Peptide Drug Discovery Services Market: Infectious Diseases, Base Scenario, 2020-2030 (USD Million)
Figure 9.16 Peptide Drug Discovery Services Market: Urological Disorders, Base Scenario, 2020-2030 (USD Million)
Figure 9.17 Peptide Drug Discovery Services Market: Hormonal Disorders, Base Scenario, 2020-2030 (USD Million)
Figure 9.18 Peptide Drug Discovery Services Market: CNS Disorders, Base Scenario, 2020-2030 (USD Million)
Figure 9.19 Peptide Drug Discovery Services Market: Other Diseases, Base Scenario, 2020-2030 (USD Million)
Figure 9.20 Peptide Drug Discovery Services Market: Distribution by Company Size, 2020, 2025 and 2030
Figure 9.21 Peptide Drug Discovery Services Market: Small Companies, Base Scenario, 2020-2030 (USD Million)
Figure 9.22 Peptide Drug Discovery Services Market: Mid-Sized Companies, Base Scenario, 2020-2030 (USD Million)
Figure 9.23 Peptide Drug Discovery Services Market: Large and Very Large Companies, Base Scenario, 2020-2030 (USD Million)
Figure 9.24 Peptide Drug Discovery Services Market: Distribution by Geography, 2020, 2025 and 2030
Figure 9.25 Peptide Drug Discovery Services Market: North America, Base Scenario, 2020-2030 (USD Million)
Figure 9.26 Peptide Drug Discovery Services Market: Europe, Base Scenario, 2020-2030 (USD Million)
Figure 9.27 Peptide Drug Discovery Services Market: Asia Pacific, Base Scenario, 2020-2030 (USD Million)
Figure 10.1 Peptides and Macrocycles Drug Discovery Service Providers: SWOT Analysis
Figure 10.2 Comparison of SWOT Factors: Harvey Ball Analysis

List Of Tables

Table 3.1 Key Strategies for Peptide Synthesis
Table 3.2 Comparison of Peptide Synthesis Processes
Table 4.1 List of Peptides and Macrocycle Drug Discovery Service Providers
Table 4.2 Peptides and Macrocycle Drug Discovery Service Providers: Information related to Drug Discovery Steps
Table 4.3 Peptides and Macrocycle Drug Discovery Service Providers: Information related to Peptide Generation Method Used
Table 4.4 Peptides and Macrocycle Drug Discovery Service Providers: Information related to Peptide Modification Method Used
Table 4.5 Peptides and Macrocycle Drug Discovery Service Providers: Other Services
Table 5.1 Benchmark Analysis: Peer Groups (Region-wise)
Table 5.2 Benchmark Analysis: Peer Groups (Based on Company Size)
Table 6.1 List of Peptides and Macrocycle Drug Discovery Platform Providers
Table 6.2 Peptides and Macrocycle Drug Discovery Platform Providers: Information related to Types of Peptides
Table 6.3 Peptides and Macrocycle Drug Discovery Platform Providers: Information related to Platform Access Model
Table 7.1 GenScript: Company Overview
Table 7.2 GenScript: Future Outlook
Table 7.3 JPT Peptide Technologies: Company Overview
Table 7.4 JPT Peptide Technologies: Future Outlook
Table 7.5 CPC Scientific: Company Overview
Table 7.6 CPC Scientific: Future Outlook
Table 7.7 IRBM: Company Overview
Table 7.8 IRBM: Future Outlook
Table 7.9 Creative Peptides: Company Overview
Table 7.10 Creative Peptides: Future Outlook
Table 7.11 Pepscan: Company Overview
Table 7.12 Pepscan: Future Outlook
Table 7.13 Interprotein Corporation: Company Overview
Table 7.14 Interprotein Corporation: Future Outlook
Table 7.15 RA Pharmaceuticals: Company Overview
Table 7.16 RA Pharmaceuticals: Future Outlook
Table 7.17 Pepticom: Company Overview
Table 7.18 Pepticom: Future Outlook
Table 7.19 PeptiDream: Company Overview
Table 7.20 PeptiDream: Future Outlook
Table 7.21 Creative Biolabs: Company Overview
Table 7.22 Creative Biolabs: Future Outlook
Table 7.23 MeSCue-Janusys: Company Overview
Table 7.24 MeSCue-Janusys: Future Outlook
Table 8.1 Peptides and Macrocycle Drug Discovery Services and Platform Providers: List of Partnerships, 2015-2019
Table 13.1 Peptides and Macrocycle Drug Discovery Service Providers: Distribution by Year of Establishment
Table 13.2 Peptides and Macrocycle Drug Discovery Service Providers: Distribution by Company Size
Table 13.3 Peptides and Macrocycle Drug Discovery Service Providers: Distribution by Location of Headquarters (Region-wise)
Table 13.4 Peptides and Macrocycle Drug Discovery Service Providers: Distribution by Location of Headquarters (Country-wise)
Table 13.5 Peptides and Macrocycle Drug Discovery Service Providers: Distribution by Type of Peptide
Table 13.6 Peptides and Macrocycle Drug Discovery Service Providers: Distribution by Drug Discovery Steps
Table 13.7 Peptides and Macrocycle Drug Discovery Service Providers: Distribution by Peptide Generation Method Used
Table 13.8 Peptides and Macrocycle Drug Discovery Service Providers: Analysis by Peptide Modification Method Used
Table 13.9 Peptides and Macrocycle Drug Discovery Service Providers: Analysis by Other Services Offered
Table 13.10 Peptides and Macrocycle Drug Discovery Platform Providers: Distribution by Year of Establishment
Table 13.11 Peptides and Macrocycle Drug Discovery Platform Providers: Distribution by Company Size
Table 13.12 Peptides and Macrocycle Drug Discovery Platform Providers: Distribution by Location of Headquarters (Region-wise)
Table 13.13 Peptides and Macrocycle Drug Discovery Platform Providers: Distribution by Location of Headquarters (Country-wise)
Table 13.14 Peptides and Macrocycle Drug Discovery Platform Providers: Distribution by Type of Peptide
Table 13.15 Peptides and Macrocycle Drug Discovery Platform Providers: Distribution by Platform Access Model
Table 13.16 Peptides and Macrocycle Drug Discovery Services and Platforms: Cumulative Distribution by Year of Partnership
Table 13.17 Peptides and Macrocycle Drug Discovery Services and Platforms: Distribution by Type of Partnerships
Table 13.18 Peptides and Macrocycle Drug Discovery Services and Platforms: Cumulative Year-Wise Distribution by Type of Partnerships
Table 13.19 Peptides and Macrocycle Drug Discovery Services and Platforms: Distribution by Type of Peptide
Table 13.20 Peptides and Macrocycle Drug Discovery Services and Platforms: Distribution by Key Focus Areas
Table 13.21 Peptides and Macrocycle Drug Discovery Services and Platforms: Most Active Players
Table 13.22 Peptides and Macrocycle Drug Discovery Services and Platforms: Country-wise Distribution
Table 13.23 Peptides and Macrocycle Drug Discovery Services and Platforms: Continent-wise Distribution
Table 13.24 Overall Peptide Drug Discovery Services Market, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 13.25 Peptide Drug Discovery Services Market: Distribution by Type of Peptides, 2020, 2025 and 2030
Table 13.26 Peptide Drug Discovery Services Market for Synthetic Peptides, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 13.27 Peptide Drug Discovery Services Market for Biologic and Recombinant Peptides, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 13.28 Peptide Drug Discovery Services Market for Macrocycles, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 13.29 Peptide Drug Discovery Services Market: Distribution by Drug Discovery Steps, 2020, 2025 and 2030
Table 13.30 Peptide Drug Discovery Services Market for Target Identification and Validation, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 13.31 Peptide Drug Discovery Services Market for Hit Identification, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 13.32 Peptide Drug Discovery Services Market for Lead Generation, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 13.33 Peptide Drug Discovery Services Market for Lead Optimization, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 13.34 Peptide Drug Discovery Services Market: Distribution by Therapeutic Area, 2020, 2025 and 2030
Table 13.35 Peptide Drug Discovery Services Market for Oncological Disorders Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 13.36 Peptide Drug Discovery Services Market for Metabolic Disorders, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 13.37 Peptide Drug Discovery Services Market for Cardiovascular Disorders, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 13.38 Peptide Drug Discovery Services Market for Infectious Diseases, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 13.39 Peptide Drug Discovery Services Market for Urological Disorders, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 13.40 Peptide Drug Discovery Services Market for Hormonal Disorders, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 13.41 Peptide Drug Discovery Services Market for CNS Disorders, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 13.42 Peptide Drug Discovery Services Market for Other Diseases, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 13.43 Peptide Drug Discovery Services Market: Distribution by Company Size, 2020, 2025 and 2030
Table 13.44 Peptide Drug Discovery Services Market for Small Companies, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 13.45 Peptide Drug Discovery Services Market for Mid-Sized Companies, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 13.46 Peptide Drug Discovery Services Market for Large and Very Large Companies, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 13.47 Peptide Drug Discovery Services Market: Distribution by Geography, 2020, 2025 and 2030
Table 13.48 Peptide Drug Discovery Services Market for North America, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 13.49 Peptide Drug Discovery Services Market for Europe, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 13.50 Peptide Drug Discovery Services Market for Asia, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)

Listed Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  1. 3B Pharmaceuticals
  2. AI Squared
  3. AiCuris
  4. Aileron Therapeutics 
  5. Alexion
  6. Ampersand Capital Partners
  7. Apigenix
  8. Apitope
  9. Asahi Kasei Pharma
  10. Astellas Pharma
  11. AstraZeneca
  12. Aurigene Discovery Technologies
  13. Bayer
  14. Bicycle Therapeutics
  15. BIND Therapeutics
  16. Bio-Synthesis
  17. Blue Ridge Biosciences
  18. Boehringer Ingelheim
  19. Bristol-Myers Squibb
  20. Bruker
  21. Cambridge Research Biochemicals
  22. ChemBridge
  23. ChemPartner
  24. Circle Pharma 
  25. CMDBioscience
  26. CPC Scientific
  27. Creative Biolabs 
  28. Creative Peptides
  29. Cyclenium Pharma
  30. Cyclogenix 
  31. Dementia Discovery Fund
  32. Domainex
  33. Eli Lilly
  34. Encycle Therapeutics
  35. Eurofins
  36. Fraunhofer Institute 
  37. EMC Microcollection
  38. Fujitsu 
  39. Fundación MEDINA
  40. Genentech 
  41. GenScript
  42. Gilead
  43. Grey Matter
  44. Gubra
  45. GVK BIO
  46. Hanmi
  47. Haplogen
  48. Heptares Therapeutics
  49. Interprotein Corporation
  50. Ipsen
  51. IRBM
  52. Isogenica
  53. Janssen Pharmaceuticals
  54. JCR Pharmaceuticals
  55. Jitsubo
  56. JPT Peptide Technologies 
  57. Kallyope
  58. Kawasaki Medical School
  59. Kleo Pharmaceuticals
  60. KYORIN Pharmaceutical
  61. Lanthio Pharma
  62. Maastricht University
  63. Macrocyclics
  64. McGill University 
  65. Menten 
  66. MercachemSyncom
  67. Merck 
  68. MeSCue-Janusys
  69. Mimotopes
  70. Morphosys
  71. Navigen Pharmaceuticals
  72. Neuland Laboratories
  73. New England BioGroup
  74. Nihon Medi-Physics 
  75. Nimble Therapeutics
  76. Novartis
  77. Novo Nordisk 
  78. NUMAFERM
  79. Nuritas
  80. Oncodesign
  81. Ono Pharmaceutical 
  82. Orbit Discovery
  83. Oxford University
  84. Pepscan
  85. Pepticom
  86. Peptides International
  87. PeptiDream
  88. Pfizer
  89. Phylogica Limited 
  90. Polyphor
  91. Prestwick Chemical 
  92. Priveel Peptides
  93. ProteoGenix
  94. Provepharm Life Solutions
  95. Ra Pharma®
  96. Red Glead Discovery
  97. RS Synthesis
  98. Sanofi
  99. Santen Pharmaceutical
  100. Sapience Therapeutics
  101. Senn Chemicals
  102. Shionogi
  103. Smartox Biotechnology
  104. Sosei Group 
  105. Taisho Pharmaceutical
  106. Taros
  107. TCG Lifesciences 
  108. Teijin Pharma
  109. Thermo Fisher Scientific
  110. Oxurion (previously known as ThromboGenics)
  111. Tokyo Institute of Technology
  112. UCB
  113. UniQuest
  114. University of Bath
  115. Zealand Pharma

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 4,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com